Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Carcinoma, Non-Small-Cell Lung
Female
Humans
Immunoconjugates
Lung Neoplasms
Male
Middle Aged
Neoplasm Staging
Proto-Oncogene Proteins c-met
Time Factors

authors with profiles

Everett E. Vokes